TABLE 2

Characteristics of Tacrolimus and Pimecrolimus Use, Pre- (2001–2004) and Postregulatory (2007–2009) Action

TacrolimusPimecrolimus
% of Total UsersPa% of Total UsersPa
2001–20042007–20092001–20042007–2009
All children <20 yb
N = 43 556N = 6030N = 297 853N = 36 311
 Previous AD or eczema diagnosis33.234.5.0420.725.8<.001
 Previous TCS use33.241.5<.00116.122.8<.001
Children <2 yb
N = 15 965N = 1354N = 140 047N = 12 221
 Users <2 y36.722.5<.00147.033.7<.001
 High strength use27.427.2.9NANA
  • NA, not available; TCS, topical corticosteroid.

  • a χ2 P values comparing pre- and postintervention periods.

  • b 183-d clean period for children ≥1 y; 30-d clean period for children <1 y.